期刊文献+

伐地那非的分子学研究 被引量:1

Molecular Studies of Vardenafil
下载PDF
导出
摘要 PDE5抑制剂在治疗ED方面的巨大成功使人们将注意力集中在更好地探讨各种抑制剂和PDE5的特征上,这些结构特征是PDE5抑制剂与PDE5的催化位点之间高亲和力和相互作用的基础。新近的分子学研究发现,伐地那非与PDE5的亲和力高,结合后解离慢,这就解释了在临床上该药可以低剂量发挥疗效、起效快速、持久等特点。研究也揭示了伐地那非的这些分子特点主要是由其环状结构决定的。 The remarkable therapeutic success of PDE5 inhibitors in the treatment of male erectile dysfunction has focused the attention of the researchers on better defining the properties of the individual inhibitors and PDE5 that contribute to the high affinity of these inhibitors for interaction with the PDE5 catalytic site. Recent molecular studies have demonstrated that vardenafil has high affinity for PDE5 and low dissociation rate from PDE5, which serves to explain why vardenafil works with low dosage, onsets quickly and has durative action in clinical practice. Moreover, the potency of vardenafil depends on its ring structure that resembles the purine moiety in cGMP.
作者 姜辉
出处 《中华男科学杂志》 CAS CSCD 2005年第5期396-399,共4页 National Journal of Andrology
关键词 PDE5抑制剂 伐地那非 分子学研究 PDE5 inhibitor vardenafil molecular study
  • 相关文献

参考文献14

  • 1Francis SH, Corbin JD. Cyclic nucleotide-dependent protein kinases: intracellular receptors for camp and cGMP action[ J]. Crit Rev Clin Lab Sci, 1999, 36(4): 275-328.
  • 2Lincoln TM, Dey N, Sellak H. cGMP dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression [ J ]. J Appl Physiol, 2001, 91 ( 3 ):1421-1430.
  • 3Schlossmann J, Feil R, Hofmann F. Signaling through NO and cGMP-dependent protein kinase [ J ]. Ann Med, 2003, 35 ( 1 ):21-27.
  • 4Ignarro LJ, Degnan JN, Baricos WH, et al. Activation of purified guanylate cyclase by nitric oxide requires heme: comparison of heme-deficient, beme-reconstituted, and beme-containing forms of soluble enzyme from bovine lung[ J]. Biochim Biophys Acta,1982, 718(1): 49-59.
  • 5Ignarro LJ, Bush PA, Buga GM, et al. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle [ J ]. Biochem Biophys Res Commum, 1990, 170(2): 843-850.
  • 6Rajfer J, Aronson WJ, Bush PA, et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to non-adrenergic, noncholinergic neurotransmission [ J ]. N Engl J Med, 1992,326 ( 2 ): 90-94.
  • 7Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil[ J]. J Biol Chem, 1999, 274(20) :13729-13732.
  • 8Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors[J]. Int J Clin Pract, 2002, 56(6): 453-459.
  • 9Rotella DP. Phosphodiesterase 5 inhibitors: current status and potential applications[ J]. Nat Rev Drug Discov, 2002, 1 (9) :674-682.
  • 10Francis SH, Corbin JD. Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists[ J]. Current Urology Reports, 2003, 4(6): 457-465.

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部